Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its prognostic value. Mean LINE1 methylation, a validated surrogate measure for global methylation, was measured in DNA from 67 tumor biopsies. Additionally, cell-free circulating DNA (cfDNA) in plasma samples from 74 patients was tested to assess the feasibility of global hypomethylation as a biomarker in liquid biopsies. LINE1 methylation was assessed using a commercially available kit, based on pyrosequencing of PCR amplified bisulfite-treated DNA. Global hypomethylation was detected in a subset of cases and was associated with poor overall survival in both tumor biopsies (P = .001) and cfDNA (P = .009). It was the strongest risk factor in multivariate analysis in both biopsies (HR: 10.65, CI: 2.03-55.81, P = .005) and cfDNA (HR: 11.87, CI: 2.80-50.20, P = .001), outperforming conventional clinical risk factors. Finally, hierarchical cluster analyses were performed for the cfDNA samples using previously published gene-specific methylation data. This analysis shows that global hypomethylation co-occurs with other epigenetic abnormalities, including DAPK1 promoter hypermethylation. In conclusion, we have shown that global hypomethylation is strongly associated with poor survival in DLBCL both when present in tumor biopsy DNA and when detected in plasma cfDNA, and has potential for clinical application as a prognostic biomarker.

Original languageEnglish
JournalAmerican Journal of Hematology
Volume92
Issue number7
Pages (from-to)689-694
Number of pages6
ISSN0361-8609
DOIs
Publication statusPublished - Jul 2017

    Research areas

  • Adult, Aged, Biomarkers, Tumor, Biopsy, Cluster Analysis, DNA Methylation, DNA, Neoplasm, Death-Associated Protein Kinases, Epigenesis, Genetic, Female, Humans, Kaplan-Meier Estimate, Long Interspersed Nucleotide Elements, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Neoplasm Staging, Prognosis, Promoter Regions, Genetic, Proportional Hazards Models, Retrospective Studies, Journal Article

ID: 51632430